Allergy Therapeutics (FRA:HHU) Valuation Rank


FRA:HHU Allergy Therapeutics PLC FRA:HHU
39 GF Score
Price €0.07
GF Value €0.03
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Allergy Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Allergy Therapeutics Valuation Rank Related Terms

FRA:HHU
39GF Score
Allergy Therapeutics PLC FRA:HHU
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Allergy Therapeutics (FRA:HHU) Overvalued in 2026?

Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued. The current stock price of €0.07 is trading 136.7% above its estimated GF Value™ of €0.03. GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:HHU:

  • Valuation Rank:
  • GF Value™: €0.03 vs. price of €0.07 (136.7% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the FRA:HHU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAAGY:UKHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
39GF Score

Get the complete analysis for FRA:HHU

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.03
GF Value